Glenmark Pharmaceuticals has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Clobetasol Propionate Foam, 0.05%, a generic version of Olux®1 Foam, 0.05%, of Mylan Pharmaceuticals, Inc.
According to IQVIA™ sales data for the 12 month period ending December 2018, the Olux® Foam, 0.05% market2 achieved annual sales of approximately $50.9 million
0 thoughts on “Glenmark Pharmaceuticals receives USFDA approval for Clobetasol Propionate Foam”